Brunner, A M
Fathi, A T
Chen, Y B
Article History
Received: 12 April 2016
Accepted: 25 April 2016
First Online: 20 June 2016
Competing interests
: ATF has participated on advisory boards for Agios and Merck and received funding for clinical research from Celgene and Takeda. YBC has received consulting fees from Bayer, Seattle Genetics and Takeda, and funding for clinical research from Celgene, Novartis, Takeda, Bayer and Seattle Genetics. AMB declares no conflict of interest.